http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022341939-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9855f853f24337072ce02f44383942c9
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01J49-26
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20
filingDate 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acb081db25f2b1771a4006eef12de0b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31ec26b9595dc4e831ead4e17199ae13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55ec57ea1f041aa79da4301ecc94d8f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ef2cb9ed9b3f6306bd1d991ed744f35
publicationDate 2022-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2022341939-A1
titleOfInvention Predictive test for identification of early stage nsclc stage patients at high risk of recurrence after surgery
abstract A method for predicting whether an early stage (IA, IB) non-small-cell lung cancer (NSCLC) patient is at a high risk of recurrence of the cancer following surgery involves subjecting a blood-based sample from the patient (obtained prior to, at, or after the surgery) to mass spectrometry and classification with a computer implementing a classifier. If the patients blood sample is classified as “high risk”, highest risk“or the equivalent, the patient can be guided to more aggressive treatment post-surgery. The classifier, or combination of classifiers, can be arranged in a hierarchical manner to make intermediate classifications, such as intermediate/high or intermediate/low, as well as low risk” or “lowest risk” classifications. Such additional classifications may guide clinical decisions as well.
priorityDate 2019-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID338446
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID83516
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID553418
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID637775
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID10891
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID40562
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID19017
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID700806
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423136
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID479127
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID700806
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412129306

Total number of triples: 33.